AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Aileron Therapeutics Inc (NASDAQ:ALRN)
2.05 USD
-0.060 2.844%| Previous Close (in USD) | 2.11 |
|---|---|
| Change | -0.060 2.844% |
| 52 W H/L (in USD) | 7.420/1.610 |
| EBITDA (in USD) | -25.396M |
| PE Ratio | -- |
| Volume | 124748 |
| Diluted Eps TTM | -2.88 |
| Total Assets (in USD) | 119.286M |
|---|---|
| Total Liabilities (in USD) | 112.399M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 17.338M |
| Market Cap (in USD) | 45.932 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -17.008M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
Employees: 15
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Manuel C. Aivado M.D., Ph.D. | Pres, CEO & Director | 1970 |
| 2. | Ms. Susan L. Drexler CPA, M.B.A. | Interim CFO, Principal Financial Officer & Principal Accounting Officer | 1970 |
| 3. | Dr. D. Allen Annis Ph.D. | Sr. VP of Research | 1973 |
| 4. | Dr. James Brian Windsor Ph.D. | CEO & Director | 1967 |
| 5. | Mr. Charles T. Garner | Principal Financial & Acconting Officer | 1976 |
| 6. | Dr. James Brian Windsor Ph.D. | CEO, President & Director | 1966 |
| 7. | Mr. Timothy M. Cunningham CPA, M.B.A. | Interim CFO & Principal Accounting Officer | 1963 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.140 0.208% | 67.62 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+0.510 0.756% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-3.525 0.791% | 445.82 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.870 0.167% | 520 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -27.329M | -26.205M | -21.157M | -29.369M | -31.547M |
| Minority Interest | - | - | - | - | - |
| Net Income | -27.011M | -25.764M | -21.818M | -28.782M | -31.547M |
| Selling General Administrative | 9.68M | 9.597M | 9.33M | 12.293M | 13.454M |
| Gross Profit | - | - | - | - | -18.448M |
| Reconciled Depreciation | 0.169M | 0.121M | 0.163M | 0.155M | 0.218M |
| Ebit | -27.647M | -26.605M | -20.496M | -29.956M | -31.902M |
| Ebitda | -27.478M | -26.884M | -19.672M | -29.801M | -31.684M |
| Depreciation And Amortization | 0.169M | -0.279M | 0.824M | 0.155M | 0.218M |
| Operating Income | -27.647M | -26.605M | -20.496M | -29.956M | -31.902M |
| Other Operating Expenses | 27.647M | 26.605M | 20.496M | 29.956M | 31.902M |
| Interest Expense | -0.318M | 0.4M | 0M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 0.3M | - | - | 0.587M | 0.355M |
| Net Interest Income | 0.3M | - | - | 0.587M | 0.355M |
| Income Tax Expense | -0.318M | -0.441M | 0.661M | -0.587M | 0.355M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 27.647M | 26.605M | 20.496M | 29.956M | 31.902M |
| Cost Of Revenue | - | - | - | - | 18.448M |
| Total Other Income Expense Net | 0.318M | 0.4M | -0.661M | 0.587M | 0.355M |
| Net Income From Continuing Ops | -27.329M | -26.164M | -21.157M | -29.369M | -31.547M |
| Net Income Applicable To Common Shares | -27.329M | -26.164M | -21.157M | -29.369M | -31.547M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 119.286M | 22.007M | 48.481M | 16.341M | 26.473M |
| Intangible Assets | 79.2M | - | - | - | - |
| Other Current Assets | 0.928M | 0.606M | 2.219M | 1.928M | 1.247M |
| Total Liab | 112.399M | 3.384M | 4.577M | 4.179M | 10.425M |
| Total Stockholder Equity | 6.887M | 18.623M | 43.904M | 12.162M | 16.048M |
| Other Current Liab | 3.147M | 1.631M | 3.205M | 2.196M | 0.352M |
| Common Stock | 0.091M | 0.091M | 0.091M | 0.044M | 0.028M |
| Capital Stock | 0.091M | 0.091M | 0.091M | 0.044M | 0.028M |
| Retained Earnings | -288.517M | -272.785M | -245.456M | -219.292M | -198.135M |
| Good Will | 6.33M | - | - | - | - |
| Other Assets | 0M | 0.024M | 0.024M | - | 0.568M |
| Cash | 17.338M | 5.194M | 3.6M | 7.046M | 5.311M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 4.385M | 3.384M | 4.508M | 3.96M | 5.839M |
| Current Deferred Revenue | - | - | - | - | 3.589M |
| Net Debt | 74.12M | -5.161M | -3.438M | -6.659M | -0.279M |
| Short Term Debt | 0.048M | 0.033M | 0.093M | 0.168M | 0.446M |
| Short Long Term Debt | - | - | - | 0.168M | - |
| Short Long Term Debt Total | 91.458M | 0.033M | 0.162M | 0.387M | 5.032M |
| Other Stockholder Equity | 203.966M | 291.365M | 289.282M | 231.412M | 214.148M |
| Property Plant Equipment | - | 0.11M | 0.28M | 0.015M | 6.355M |
| Total Current Assets | 18.266M | 21.873M | 48.177M | 16.326M | 19.55M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 16.048M | 42.333M | 6.759M | 12.967M |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | 0.219M | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 1.19M | 1.72M | 1.21M | 1.596M | 1.452M |
| Accumulated Other Comprehensive Income | -0.063M | -0.048M | -0.013M | -0.002M | 0.007M |
| Non Currrent Assets Other | 2.193M | 0.024M | 0.024M | - | 0.568M |
| Non Current Assets Total | 101.02M | 0.134M | 0.304M | 0.015M | 6.923M |
| Capital Lease Obligations | 0.048M | 0.033M | 0.162M | 0M | 5.032M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 26.459M | -35.917M | 6.411M | -2.663M | 29.111M |
| Total Cashflows From Investing Activities | 26.459M | -35.917M | 6.411M | -2.814M | 24.688M |
| Total Cash From Financing Activities | 0M | 55.657M | 15.8M | 23.964M | 2.515M |
| Net Income | -27.329M | -26.164M | -21.157M | -29.369M | -31.547M |
| Change In Cash | 1.594M | -4.014M | 1.735M | -5.324M | -0.723M |
| Begin Period Cash Flow | 3.625M | 7.639M | 5.904M | 11.228M | 11.951M |
| End Period Cash Flow | 5.219M | 3.625M | 7.639M | 5.904M | 11.228M |
| Total Cash From Operating Activities | -24.865M | -23.754M | -20.476M | -26.474M | -27.926M |
| Depreciation | 0.169M | 0.121M | 0.163M | 0.155M | 0.218M |
| Other Cashflows From Investing Activities | - | - | 0.208M | -2.663M | 29.111M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | 0.165M | 0.042M |
| Other Cashflows From Financing Activities | 26.459M | 0.074M | 0.387M | 0.165M | 2.515M |
| Capital Expenditures | 0M | 0.157M | 0.005M | 0.151M | 4.423M |
| Change In Working Capital | 0.42M | 0.242M | -1.28M | 0.85M | 0.376M |
| Other Non Cash Items | -0.208M | -0.213M | -0.095M | -0.226M | -0.253M |
| Free Cash Flow | -24.865M | -23.911M | -20.481M | -26.625M | -32.349M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 8 months ago | 3261 |
| 2. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 8 months ago | 2670 |
| 3. | SSgA U.S. Total Market Index Strategy | 11 months ago | 2354 |
| 4. | Northern Trust Wilshire 5000 | 8 months ago | 1319 |
| 5. | State St US Ttl Mkt Indx SL Cl I | 7 months ago | 400 |
| 6. | Fidelity U.S. Equity Index Ins Trust | 7 months ago | 175 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 412220 |
| 8. | Fidelity Extended Market Index | 7 months ago | 111248 |
| 9. | iShares Micro-Cap ETF | 6 months ago | 45857 |
| 10. | Fidelity Total Market Index | 7 months ago | 35681 |
| 11. | Fidelity Series Total Market Index | 7 months ago | 25112 |
| 12. | Northern Trust Extended Eq Market Idx | 8 months ago | 21130 |
| 13. | NT Ext Equity Mkt Idx Fd - L | 8 months ago | 21130 |
| 14. | Vanguard U.S. Eq Idx £ Acc | 7 months ago | 12774 |
| 15. | Fidelity Nasdaq Composite Index | 7 months ago | 9226 |
| 16. | Spartan Total Market Index Pool E | 7 months ago | 7509 |
| 17. | Spartan Extended Market Index Pool E | 7 months ago | 6733 |
| 18. | State St US Extended Mkt Indx NL Cl C | 6 months ago | 5740 |
| 19. | 1290 VT Micro Cap K | 8 months ago | 3327 |
| 20. | NT Ext Equity Mkt Idx Fd - NL | 8 months ago | 3314 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Cable Car Capital LLC | 8 months ago | 420000 |
| 2. | Sigma Planning Corp | 8 months ago | 212410 |
| 3. | Gagnon Securities LLC | 8 months ago | 71761 |
| 4. | University Of Texas Investment Mgmt Co | 8 months ago | 1403339 |
| 5. | Alyeska Investment Group, L.P. | 8 months ago | 540000 |
| 6. | Nantahala Capital Management, LLC | 8 months ago | 464367 |
| 7. | Vanguard Group Inc | 8 months ago | 432201 |
| 8. | Prosight Management, LP | 8 months ago | 372157 |
| 9. | RIMA MANAGEMENT, LLC | 8 months ago | 230895 |
| 10. | Geode Capital Management, LLC | 8 months ago | 229817 |
| 11. | BlackRock Inc | 11 months ago | 31285 |
| 12. | Northern Trust Corp | 8 months ago | 25763 |
| 13. | Blair William & Co | 8 months ago | 25602 |
| 14. | Newbridge Financial Services Group, Inc. | 8 months ago | 25000 |
| 15. | Renaissance Technologies Corp | 8 months ago | 13164 |
| 16. | KG&L Capital Management,LLC | 8 months ago | 13000 |
| 17. | State Street Corp | 8 months ago | 10404 |
| 18. | Warberg Asset Management LLC | 8 months ago | 10000 |
| 19. | Wells Fargo & Co | 8 months ago | 9544 |
| 20. | Texas Capital Bank Wealth Management Services Inc | 8 months ago | 26171 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...